Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

27461 results about "Carcinosis" patented technology

Carcinosis, or carcinomatosis, is disseminated cancer, forms of metastasis, whether used generally or in specific patterns of spread.

Compositions and methods for modulating circulating factors

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.
Owner:FLAGSHIP ENTREPRENEURSHIP & INNOVATION NO 7 CO LTD

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer

The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3 to R5, ring A, ring B, p, q, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments / medical uses, especially as agents for treatment and / or prevention of oncological diseases.
Owner:BOEHRINGER INGELHEIM INT GMBH +1

KRAS inhibitors

The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
Owner:BRISTOL MYERS SQUIBB CO

Compound having Anti-KRAS mutant tumor activity

Provided are a compound having the structure represented by formula (I) and capable of being used as a KRAS inhibitor, a pharmaceutical composition comprising the compound, a method for preparing the compound, and a use of the compound in treatment of cancer.
Owner:TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED

Small molecule protein degraders of KRAS g12d mutant

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

PARP1 inhibitor compounds

A PARP1 inhibitor compound has a structure of: Formula (I), R1 and R4 are independently selected from H and an organic group. R2 and R3 are independently absent, H, or an organic group. Z1 and Z2 are independently C or N. L has the structure: Formula (II). Each X1 is independently selected from C and N. Each X2 is independently selected from C, N, O and S. n, m, p, q, r and s are each in the range 0 to 6. m+n, p+q, and r+s are each in the range 2 to 6. Each R5A, R5B, R5C, and R6 is independently absent, H, or an organic group. Qa, Qb, Qc are each independently a bond or an organic linker. The compounds are for use in medicine, e.g. for use in treating cancer. Also provided are compositions and kits comprising the compounds, and methods of synthesising the compounds.
Owner:DUKE STREET BIO LTD

KRAS proteolysis targeting chimeras

Provided herein are KRAS proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS PROTACs, and methods of making and using the KRAS PROTACs, e.g., to promote degradation of KRAS and / or treat KRAS-associated cancers. In an embodiment, the KRAS PROTAC has the following structural formula: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., Ring A, X4, Y, R2, R3, R4, L', Degron) are as described herein.
Owner:PAQ THERAPEUTICS INC

Heterobifunctional compounds for the degradation of KRAS protein

PCT designated stage expiredWO2025006753A2Organic active ingredientsOrganic chemistryViral OncogeneRat sarcoma virus
The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
Owner:MERCK PATENT GMBH +2

Heterobifunctional compounds for the degradation of kras

PCT designated stage expiredWO2025006783A2Organic active ingredientsOrganic chemistryViral OncogeneRat sarcoma virus
The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
Owner:ANDERSON COREY DON +3

Ras inhibitors and methods of use thereof

PCT designated stage expiredWO2025076523A1Organic active ingredientsOrganic chemistryDiseaseFormulary
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. Pharmaceutical compositions and methods of making various indene compounds are provided. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).
Owner:KESTREL THERAPEUTICS INC

Detecting mutations and ploidy in chromosomal segments

The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.
Owner:NATERA INC

KRAS proteolysis targeting chimeras

Provided herein are KRAS proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS PROTACs, and methods of making and using the KRAS PROTACs, e.g., to promote degradation of KRAS and / or treat KRAS-associated cancers. In an embodiment, the KRAS PROTAC has the structural formula (I) or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein.
Owner:PAQ THERAPEUTICS INC

Ras inhibitors and methods of use thereof

The disclosure provides compounds, e.g., compounds of Formulae (I)-(III), and their use in treating medical diseases or disorders, such as cancer. Pharmaceutical compositions and methods of making various indene compounds are provided. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).
Owner:KESTREL THERAPEUTICS INC

KRAS inhibitors

The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
Owner:BRISTOL MYERS SQUIBB CO

Fused pyridines for the treatment of cancer and other indications

PCT designated stage expiredWO2025034858A1Organic active ingredientsOrganic chemistrySmall GTPaseBiochemistry
Provided herein are compounds of Formula I" and Formula II and compositions thereof that are capable of disrupting, interrupting, and / or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof.
Owner:THERAS INC +2

Combination therapies for the treatment of cancer

Provided is combination therapies that involve a construct has a TIGIT-binding moiety and a PVRIG-binding moiety and a KRAS G12C inhibitor for treating cancer with KRAS G12C mutations. In some cases, the construct is a multispecific antibody or a bispecific antibody that recognizes PVRIG and TIGIT.
Owner:D3 BIO (WUXI) CO LTD

Fused ring compound and use thereof in KRAS inhibitor

A fused ring compound, a pharmaceutical composition comprising same, and the use thereof. The compound has a structure as represented by formula (I), or is a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a metabolite, a metabolic precursor, an isotope-substituted form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a co-crystal thereof. The compound can be used for treating one or more cancers caused by KRAS mutation.
Owner:CHENGDU HYPERWAY PHARM CO LTD +1

Fused pyridazines for the treatment of cancer and other indications

PCT designated stage expiredWO2025034849A1Organic active ingredientsOrganic chemistryPyridazineSmall GTPase
Provided herein are compounds of Formula (I) and Formula (II) and compositions thereof that capable of disrupting, interrupting, and / or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Kα). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof. (I) (II)
Owner:THERAS INC +2

Substituted 2-amino-9-(3,3-difluoropiperidin-4-YL)-7,9-dihydro-8h-purin-8-one compounds and their use in treating cancer

The present invention discloses substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8H-purin-8-one compounds compounds having the structural formula represented by formula (I): The substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8H-purin-8-one compounds, derivatives and pharmaceutically acceptable salts thereof of the present invention are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a DNA-dependent protein kinase (DNA-PK) and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, glioma, glioblastoma, DIPG, and the like either as monotherapy or combination with other treatments, such as radiation therapy or chemotherapy.
Owner:ZHONG WEI

Detecting mutations and ploidy in chromosomal segments

The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.
Owner:NATERA INC

Use of heterocyclic Anti-tumor compound

The invention relates to the technical field of medicines, and provides a use of a heterocyclic anti-tumor compound, in particular a use of the heterocyclic anti-tumor compound in the preparation of a medicine for preventing and / or treating tumors or cancers. The compound has a tri-heterocyclic structure (for example, a structure as shown in formula (B)), has a novel structure, and provides a new direction for the development of SOS1 inhibitor drugs.
Owner:CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD

Pyrimido-pyridine compound, pharmaceutical composition thereof and use thereof

A pyrimido-pyridine compound, a pharmaceutical composition thereof and the use thereof. The compound and the pharmaceutical composition thereof as KRAS G12D inhibitors can be used for preparing a drug for preventing or treating KRAS G12D-related diseases, and can be particularly used for preparing a drug for preventing or treating cancers.
Owner:SUNSHINE LAKE PHARMA CO LTD

2-(3,8-diazabicyclo[3.2.1]octan-3-YL)-1,3,5-triazine derivatives as KRAS g12d inhibitors for the treatment of cancer

Compounds are provided which can inhibit KRAS G12D. Also provided are pharmaceutical compositions and medical uses of the same, including the use in treating or preventing conditions such as cancers.
Owner:SANOFI SA(FR)

Detecting mutations and ploidy in chromosomal segments

The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.
Owner:NATERA INC